January 2019

 

In this Supplement

Shifting the SFA Treatment Paradigm

Global thought leaders discuss the ELUVIA DES IMPERIAL Trial results and its influence on treatment decisions

Issue

Supplement

Download a PDF of this supplement

IMPERIAL 12-Month Full Cohort and Long Lesion Sub-Study Results

Sustained drug-release in the SFA drives superior results.

By William A. Gray, MD; Additional commentary by Prof. Stefan Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA, FSIR

A Roundtable Discussion on Results From the First Head-to-Head DES SFA Trial: IMPERIAL

A multidisciplinary panel of PAD experts discuss the impact on patient care and the health care system and how these results may shift current treatment algorithms.

With Michael R. Jaff, DO; Gary M. Ansel, MD, FACC; William A. Gray, MD; Steve Henao, MD, FACC, FACS; and Robert A. Lookstein, MD

Discussing the IMPERIAL Data in Practice

Two vascular experts share their reactions to hearing the results of the first head-to-head peripheral DES trial.

With Yann Gouëffic, MD, PhD; and Andrew Holden, MBChB, FRANZCR, EBIR
 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.